Renal cell carcinoma detection and systemic therapy with tumour-affine gallium-67 and with yttrium-90 citrate solutions
Shukla, S.K.; Limouris, G.S.; Cusumano, R.; Acconcia, A.; Cipriani, C.; Argiro, G.; Atzei, G.; Boemi, S.
Anticancer Research 17(3b): 1713-1718
1997
ISSN/ISBN: 0250-7005 PMID: 9179224 Document Number: 470372
Background. There have been no major advances in the systemic detection of renal cell carcinoma (RCC) and its unpredictable metastases. Surgery, thus, remains the mainstay of the curative treatment for the localized disease. The purpose of the present study has been to systemically detect and treat advanced RCC respectively with Ga-67 and Y-90 radiopharmaceuticals containing tumour-affine species. Patients and methods. Thirty-three RCC patients were imaged with Tc-99m-MDP and then with Ga-67 citrate solution in order to detect RCC and its metastases. Yttrium-90 citrate solution, containing the radionuclide species chromatographically and electrophoretically identical to those in RCC-affine Ga-67 solution, was administered iv; for systemic therapy of advanced RCC Total-body distribution of Y-90 was studied with a gamma-camera equipped with an ultra-high-sensitivity collimator. The efficacy of the therapy was studied by the clinical condition of the patient and by the total-body scintigraphic imaging with Tc-99m-MDP and with Ga-67 citrate solution. Results. Ga-67 detects RCC bone metastases better than Tc-99m-MDP. Systemic therapy of RCC metastasized to bones, lung and brain was obtained with RCC-affine Y-90 citrate solution. Conclusions. Third group metal radionuclides, Ga-67 and Y-90, detect and treat advanced RCC.